Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor–Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial - Concepedia

Concepedia

Publication | Open Access

Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor–Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial

DOI Full Paper Access

19

Citations

17

References

2022

Year

S.B. Vliek, Iris Noordhoek, Elma Meershoek‐Klein Kranenbarg, Annelot G.J. van Rossum, Vincent O. Dezentjé, Agnes Jager, J.W. Esmeralda Hokken, Hein Putter, Annette W.G. van der Velden, Mathijs P. Hendriks,

Journal of Clinical Oncology

Abstract

In postmenopausal women with ER+ breast cancer, adjuvant ibandronate 50 mg once daily does not improve DFS and should not be recommended as part of standard treatment regimens.

References

	Year	Citations

Page 1